Menu
Back to Journals » Drug Design, Development and Therapy » Volume 3 » default
Drug Design, Development and Therapy
ISSN: 1177-8881
- View all (3883)
- Volume 17, 2023 (127)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Archive: Volume 3, 2009
Review of the pharmacology and clinical studies of micafungin
Alison M Bormann, Vicki A Morrison
Drug Design, Development and Therapy 2009, 3:295-302
Published Date: 10 December 2009
Effect of combinations of antiviral drugs on herpes simplex encephalitis
Bryan M Gebhardt, Federico Focher, Richard Eberle, et al
Drug Design, Development and Therapy 2009, 3:289-294
Published Date: 9 December 2009
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent
Brian Casserly, James R Klinger
Drug Design, Development and Therapy 2009, 3:269-287
Published Date: 30 November 2009
Conivaptan and its role in the treatment of hyponatremia
Jalal K Ghali, Jareer O Farah, Suleiman Daifallah, et al
Drug Design, Development and Therapy 2009, 3:253-268
Published Date: 16 October 2009
Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
Ann Janssens, Marc Boogaerts, Gregor Verhoef
Drug Design, Development and Therapy 2009, 3:241-252
Published Date: 14 October 2009
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
Gisela I Robles, Devada Singh-Franco
Drug Design, Development and Therapy 2009, 3:219-240
Published Date: 10 September 2009
Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
Shinichiro Ryuge, Shi-Xu Jiang, Mayuko Wada, Ken Katono, et al.
Drug Design, Development and Therapy 2009, 3:213-217
Published Date: 13 July 2009
T10B9 monoclonal antibody: A short-acting nonstimulating monoclonal antibody that spares γδ T-cells and treats and prevents cellular rejection
Thomas H Waid, John S Thompson, Maria Siemionow, Stephen A Brown
Drug Design, Development and Therapy 2009, 3:205-212
Published Date: 25 June 2009
Pleiotropic vasoprotective effects of statins: The chicken or the egg?
Dimitrios Kirmizis, Dimitrios Chatzidimitriou
Drug Design, Development and Therapy 2009, 3:191-204
Published Date: 10 June 2009
Characteristics of doripenem: a new broad-spectrum antibiotic
Francisco Alvarez-Lerma, Santiago Grau, Olivia Ferrández
Drug Design, Development and Therapy 2009, 3:173-190
Published Date: 27 May 2009
Management of advanced breast cancer with the epothilone B analog, ixabepilone
William Gradishar
Drug Design, Development and Therapy 2009, 3:163-171
Published Date: 2 June 2009
Oxybutynin extended release for the management of overactive bladder: a clinical review
AM Arisco, EK Brantly, SR Kraus
Drug Design, Development and Therapy 2009, 3:151-161
Published Date: 26 May 2009
Efficacy of epicutaneous Diractin® (ketoprofen in Transfersome® gel) for the treatment of pain related to eccentric muscle contractions
Matthias Rother, Egbert J Seidel, Priscilla M Clarkson, Stefan Mazgareanu, et al.
Drug Design, Development and Therapy 2009, 3:143-149
Published Date: 19 May 2009
Indiplon in the management of insomnia
Michael D Lemon, Joe D Strain, Annie M Hegg, Debra K Farver
Drug Design, Development and Therapy 2009, 3:131-142
Published Date: 8 May 2009
Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex
Sorin J Brull, Mohamed Naguib
Drug Design, Development and Therapy 2009, 3:119-129
Published Date: 24 April 2009
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
Kari E Roberts, Ioana R Preston
Drug Design, Development and Therapy 2009, 3:111-118
Published Date: 31 March 2009
Oxidative stress-induced cell cycle blockage and a protease-independent programmed cell death in microaerophilic Giardia lamblia
Esha Ghosh, Arjun Ghosh, Amar Nath Ghosh, Tomoyoshi Nozaki, Sandipan Ganguly
Drug Design, Development and Therapy 2009, 3:103-110
Published Date: 26 March 2009
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis Giles
Drug Design, Development and Therapy 2009, 3:89-101
Published Date: 27 March 2009
Troglitazone reverses the multiple drug resistance phenotype in cancer cells
Gerald F Davies, Bernhard HJ Juurlink, Troy AA Harkness
Drug Design, Development and Therapy 2009, 3:79-88
Published Date: 17 March 2009
Newer treatments for decompensated heart failure: focus on levosimendan
Ferenc Follath
Drug Design, Development and Therapy 2009, 3:73-78
Published Date: 12 March 2009
Analysis of HSP90-related folds with MED-SuMo classification approach
Olivia Doppelt-Azeroual, Fabrice Moriaud, François Delfaud, Alexandre G de Brevern
Drug Design, Development and Therapy 2009, 3:59-72
Published Date: 26 February 2009
Alitretinoin – its use in intractable hand eczema and other potential indications
Bibi Petersen, Gregor BE Jemec
Drug Design, Development and Therapy 2009, 3:51-57
Published Date: 5 February 2009
The evolving role of alemtuzumab (Campath-1H) in renal transplantation
Phuong-Thu T Pham, Gerald S Lipshutz, Phuong-Truc T Pham, Joseph Kawahji, Jennifer S Singer, Phuong-Chi T Pham
Drug Design, Development and Therapy 2009, 3:41-49
Published Date: 23 December 2008
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases
Thomas J Polascik
Drug Design, Development and Therapy 2009, 3:27-40
Published Date: 22 December 2008
Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model
Thilo S Lange, Carolyn McCourt, Rakesh K Singh, Kyu Kwang Kim, Ajay P Singh, et al
Drug Design, Development and Therapy 2009, 3:17-26
Published Date: 17 December 2008
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC
Akito Natsume, Rinpei Niwa, Mitsuo Satoh
Drug Design, Development and Therapy 2009, 3:7-16
Published Date: 16 December 2008
Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty
Katherine A Lewis, Erica A Eugster
Drug Design, Development and Therapy 2009, 3:1-5
Published Date: 23 December 2008